Brain metastases are common and devastating complications of both breast cancer and melanoma. Although mammary carcinoma brain metastases are more frequent than those originating from melanoma, this latter has the highest tropism to the brain. Using static and dynamic in vitro approaches, here we show that melanoma cells have increased adhesion to the brain endothelium in comparison to breast cancer cells. Moreover, melanoma cells can 
INTRODUCTION
Brain metastases -which are usually late, but devastating complications of cancer -most frequently originate from lung cancer, breast cancer and melanoma. Tumor cells successfully infiltrating the brain parenchyma overcome several obstacles, including survival in the circulation, 1 extravasation through brain capillaries (reviewed in: 2 ) and resisting deleterious signals of the reactive brain stroma. 3 However, cancer cells able to migrate into and to survive in the brain will benefit of a supportive and protective microenvironment, including the dense vasculature with the opportunity of vessel co-option 4 and chemoprotection mediated by astrocytes and endothelial cells. 5 As a consequence, brain metastases have a poor prognosis.
Therefore, inhibiting extravasation of metastatic cells into the brain would be of great clinical benefit.
Diapedesis of metastatic cells through the capillaries of the brain implies adhesion of tumor cells
to the luminal surface of cerebral endothelial cells (CECs), followed by a recently described, not yet fully characterized step called incorporation into the monolayer, 6 and finally the transmigration step itself. CECs are interconnected by a continuous layer of tight junctions and form the blood-brain barrier (BBB). The BBB restricts the free movement of solutes between the blood and the central nervous system, and represents an impediment for cellular elements (leukocytes and metastatic cells) to reach the brain parenchyma (reviewed in: 7 ) . We have previously shown that melanoma cells are able to disrupt the tight junctions of CECs making possible their transmigration through the brain endothelium. 8 It is not understood however, whether breast cancer cells are able to disrupt the tight junctions or migrate preferentially transcellularly. In fact, transcellular migration of tumor cells has only been described in case of breast cancer cells during intravasation into an in vitro vascular network 9 and migration through umbilical cord endothelial cells. 10 However, to our knowledge, no data on the transmigration pathway of breast cancer cells through BBB endothelial cells exist.
Our previous results indicated that during transmigration through the brain endothelium, melanoma cells favor the mesenchymal type of cell movement. 11 This is characterized by an elongated morphology, increased proteolytic activity and is dependent on Rac activity. 12 On the other hand, the amoeboid type of tumor cell migration is characterized by rounded morphology and extensive RhoA signaling. Tumor cells can switch between these two movement types depending on the environment they move in. 13 By inhibiting Rho/ROCK signaling, and therefore triggering the mesenchymal phenotype, a significant increase in the number of melanoma cells migrating through CECs could be induced. 11 Here we aimed to compare melanoma and breast cancer cells in respect of mesenchymal vs. amoeboid migration through the brain endothelium. The question whether tumor cells prefer Rho/ROCK or Rac-dependent transendothelial migration is of clinical importance, since inhibitors of both Rho/ROCK (e.g. fasudil) and Rac pathways 14 are emerging as potential therapeutic agents.
The Rac pathway has been shown to be regulated by phosphoinositide 3-kinase (PI3K) in breast cancer cells. 15 Moreover, the PI3K/Akt/mTOR pathway is probably the most important in respect of anti-cancer treatment targets. 16 It has been shown that dysregulation of the PI3K signaling pathway is associated with the development of one-third of human cancers, including breast cancers 17 and melanomas. 18 Aberrant activation of the PI3K pathway promotes carcinogenesis, tumor angiogenesis and resistance to therapies, 19 and plays a role in cell motility as well. 20 Therefore, the first aim of our study was to compare the adhesion and transmigration properties of melanoma and breast cancer cells. The second aim was to understand the role of Rac signaling and of amoeboid vs. mesenchymal phenotype in the transmigration of breast cancer cells through the BBB. The third aim was to investigate whether PI3K inhibition has an impact on the transmigration of tumor cells through the cerebral endothelium during brain metastasis formation.
RESULTS

Adhesion and transmigration properties of melanoma and breast cancer cells in vitro
Since melanoma cells have higher propensity to metastasize to the brain than breast cancer cells, we aimed to understand whether there is any difference in the interaction of melanoma cells or breast cancer cells with the brain endothelium.
We first aimed to compare the adhesion properties of melanoma and breast cancer cells to the brain endothelium. 90 min after plating the tumor cells upon brain endothelial cells, significantly more melanoma cells than breast cancer cells were able to attach to the endothelium (Table 1) .
Therefore, we wanted to test whether the increased adhesion of melanoma cells in comparison to breast cancer cells results in an increased transmigration as well.
For studying the transmigration properties of melanoma and breast cancer cells in static conditions, we used a novel approach based on a time-lapse video setup described in the Materials and methods section. This innovative assay developed in our laboratory makes possible to follow the fate of each individual cell in time (adhesion, migration, division, etc.).
This approach eliminates the drawbacks of assays using filter inserts, where cells migrating through the endothelial monolayer but not moving through the pores of the filter cannot be considered. Moreover, several cell types (including D3 cells) cannot be properly grown on large pore-size filters due to the formation of a double monolayer on both sides of the membrane.
Comparing the transmigration properties of melanoma and breast cancer cells using the static transmigration assay, we observed that fewer breast cancer cells than melanoma cells were able to migrate through the brain endothelium ( Table 2) . The difference was significant: 27-28% of plated melanoma cells completed the transmigration process, while only 16% of breast cancer cells migrated through.
To confirm our results in physiologically more relevant conditions, we constructed a dynamic transmigration model. Brain endothelial cells were cultured in a microfluidic device ( Fig. 1A; described in details in the Material and methods section) until confluence (Suppl. video 1). After reaching confluence, a slow, physiologically relevant flow of the culture medium was initiated (300 µl/h, 1-2 dyn/cm 2 ) for 24 h. Shear stress induced elongation of endothelial cells (Suppl. Fig.   1 ). Taken together, these results show that melanoma cells are able to adhere to and migrate through the brain endothelium more effectively than breast cancer cells. This might be partly responsible for the higher propensity of melanoma cells to metastasize to the brain.
Differences in the effects of melanoma cells and breast cancer cells on the tight junctions of brain endothelial cells
We have previously observed that during transmigration melanoma cells are able to disrupt the tight junctions of cerebral endothelial cells and use (at least partly) the paracellular way of migration. 8 We were interested to understand whether breast cancer cells are also able to impair These data suggest that differences in the transendothelial migration of mammary carcinoma and melanoma cells might be partly due to differences in their ability to impair interendothelial junctions.
Inhibition of Rac or PI3K hampers the adhesion of breast cancer cells and melanoma cells to the brain endothelium
We have previously shown that inhibition of the Rho/ROCK pathway facilitates the adhesion of melanoma cells, and this effect is reversed by the Rac inhibitor EHT1864. 11 We now aimed to understand whether the same mechanism applies for breast cancer cells during adhesion to cerebral endothelial cells. In contrast to melanoma cells, ROCK inhibitors (10 µM Y27632 or 10 µM fasudil) were not able to increase the number of breast cancer cells adherent to the brain endothelium ( Interestingly, when measuring the adhesion forces using atomic force microscopy between MDA-MB-231 breast cancer and hCMEC/D3 brain endothelial cells, or A2058 melanoma and hCMEC/D3 brain endothelial cells, respectively, we could not observe any decrease in response to EHT1864 or LY294002 (Suppl. Fig. 2 ).
Inhibition of Rac or PI3K impedes the transmigration of breast cancer cells and melanoma cells through the brain endothelium in static conditions
Since inhibition of Rac or PI3K decreased the adhesion of both melanoma and breast cancer cells, we tested the effect of Rac or PI3K inhibitors on the transmigration of melanoma and breast cancer cells through brain endothelial monolayers as well ( 
Inhibition of Rac or PI3K inhibits the late phase of transmigration of breast cancer cells and the early phase of transmigration of melanoma cells through the brain endothelium in dynamic conditions
Using our dynamic model, we explored which step of transmigration of breast cancer or melanoma cells was inhibited by EHT1864 or LY294002. As previously discussed (Table 3) Taken together, our results indicate that inhibition of Rac or PI3K impairs the ability of both breast cancer and melanoma cells to adhere to and to migrate through the brain endothelium.
Differences exist however, between the velocities of the transmigration of the two tumor cell types.
Effects of Rac and PI3K inhibitors on the viability, proliferation and migration of tumor cells and brain endothelial cells
We wanted to exclude that the inhibitory effect of EHT1864 and LY294002 on the adhesion and transmigration of breast cancer and melanoma cells was due to toxicity on tumor cells. Using the EZ4U assay no toxic effect of either EHT1864 or LY294002 on A2058, MDA-MB-231 and MCF-7 cells was observed (not shown). Moreover, the EZ4U assay did not show any toxicity of EHT1864 or LY294002 on D3 brain endothelial cells. In addition, as assessed during the timelapse video experiments, the number of dividing cells was approximately 2.5% in case of MDA-LY294002. Moreover, the wound healing assay indicated no change in the migratory properties of melanoma or breast cancer cells in response to EHT1864 or LY294002 (not shown).
The Rac inhibitor EHT1864 impairs the junctional integrity of the brain endothelium
We observed that EHT1864 induced a decrease in the impedance of D3 cells, as reflected by the cell index on Fig. 6A . After an initial drop induced by the medium change, the impedance of control and LY294002-treated D3 cells recovered rapidly. However, in case of EHT1864-treated cells the recovery was not complete, and after 5 h a significant drop in the impedance was seen.
The cell impedance reflects changes in the cell number, viability and tightness of the junctions.
Since no change in the viability of D3 cells was observed using the EZ4U assay, we next investigated the possible damaging effect of the Rac inhibitor on the tight junctions. We Our results indicate that melanoma cells have increased adhesion to the brain endothelium than breast cancer cells. In order to exclude the possibility that this is due to differences in the invasive and metastatic capacities between the melanoma and breast cancer cell lines used, we used two different breast cancer cell lines: the less invasive MCF-7 and the highly migratory and metastatic MDA-MB-231. 14 We also used two different melanoma cell lines, A2058 and A375, both invasive BRAF V600E mutants, having similar propensity to metastasize to different organs, 23 A2058 being vemurafenib resistant, while A375 vemurafenib sensitive. 24 The difference between the adhesive properties of melanoma cells and either of the breast cancer cell lines was significant. Moreover, such a difference was not observed when other endothelial cell types (HUVECs, dermal microvascular cells, lymphatic endothelial cells) were used: melanoma cells had similar adhesion properties to non-cerebral endothelial cells as breast cancer cells. 25 On the other hand, incorporation of A375 into HUVECs was shown to be faster than that of MDA-MB-321. 6 We have also observed a significant difference in the number of transmigrating melanoma and breast cancer cells. The number of cells not able to migrate through the brain endothelium was much higher in case of breast cancer cells than in case of melanoma cells.
Moreover, invasive melanoma cells tended to complete the transmigration process much more rapidly than invasive breast cancer cells. These data suggest that tumor cells with higher affinity to the brain can more easily overcome the BBB; however, further studies are needed to support this hypothesis.
Differences between the ability of the two tumor cell types to migrate through the brain endothelium might be partly due to their different ability to impair the tight junctions. Our data indicate that melanoma cells are more effective in breaking down the paracellular barrier than breast cancer cells. Breast cancer cells were previously shown to be able to use not only the paracellular pathway (through interendothelial junctions), but also the transcellular pathway (through the endothelial cell body) during migration through non-cerebral endothelia. 9, 10 Our results suggest that breast cancer cells might be more effective in the transcellular type of migration than melanoma cells, these latter having increased ability to impair the tight junctions than mammary carcinoma cells. Further analyses will clarify this possible difference between the two tumor cell types.
We have also assessed the role of two signaling molecules (Rac and PI3K) in the transmigration of melanoma and breast cancer cells through the BBB. In a recent study we showed that melanoma cells prefer the Rac-dependent mesenchymal type of cell movement to the Rho/ROCK-dependent amoeboid one during transmigration through the BBB. 11 Here we show that inhibition of Rac not only impedes the adhesion and transmigration of melanoma cells, but of breast cancer cells as well. According to our previous results, ROCK inhibition induced an increase in the adhesion force between melanoma and brain endothelial cells. We hypothesized that mesenchymal cell flattening was partly responsible for this phenomenon. 11 We suppose that induction of the amoeboid phenotype using the Rac inhibitor does not have such a significant impact on the shape of tumor cells detached from the surface. Therefore, the area of contact Besides Rac, we tested the role of the PI3K/Akt/PTEN pathway, which is a key regulator of tumorigenesis and metastasis formation. BRAF-mutant melanoma cells have been shown to have higher levels of pAkt-Ser473, pAkt-Thr308 and decreased expression of PTEN. 26 The A2058
cell line used in our experiments is a V600E BRAF mutant expressing high amounts of phosphorylated Akt and low levels of PTEN. 27 It has been shown that inhibition of PI3K results in a reduction of melanoma cell transmigration through HUVECs. 28 Since brain metastases of melanoma have been shown to have significantly higher pAkt and lower PTEN levels than extracerebral metastases, 26, 29 we aimed to test whether inhibition of this pathway impedes the transmigration of melanoma cells through CECs. We observed a marked inhibition of melanoma cells able to attach to and to migrate through the brain endothelium in response to PI3K
inhibition. This is in contrast with small cell lung cancer cells, which were not affected by PI3K inhibition in their transmigration through brain microvascular endothelial cells. 30 It has been previously shown that inhibition of Rac or PI3K, but of ROCK also reduces the pulmonary microvascular endothelial cell-induced invasiveness of MDA-MB-231 with high α 5 β 1 integrin expression. 31 According to our results, breast cancer cell transendothelial migration could be partly blocked using the PI3K inhibitor LY294002 -similarly to melanoma cells.
The morphology of PI3K-inhibited tumor cells was similar to that of Rac-inhibited cells, i.e. we could see a reduction in the number of elongated, flattened cells. This suggests that PI3K
inhibition -similar to Rac inhibition -induces an amoeboid-like phenotype in both melanoma and breast cancer cells. This is not surprising because PI3K has been shown to regulate Rac through P-Rex1 in breast cancer cells 15 and several PI3K lipid products have been shown to interact with different RacGEFs. 32 In contrast to EHT1864, the PI3K inhibitor LY294002 did not affect the integrity of the BBB.
Moreover, many PI3K inhibiting agents are in different phases of clinical trials for the treatment of different cancer types. 33 Based on our results, PI3K inhibitors might turn out to have clinical benefits not only in the treatment of primary tumors, but also in preventing brain metastasis formation of breast cancer and melanoma cells.
In conclusion, we have shown that invasive melanoma cells have an increased capacity to attach to, to migrate through and to impair the tight junctions of the brain endothelium than breast cancer cells. In addition, inhibition of Rac or PI3K decreases the number of both melanoma and breast cancer cells able to transmigrate through cerebral endothelial cells; however, Rac inhibition (but not PI3K inhibition) impairs the junctional integrity of the blood-brain barrier.
Since inhibitors of the PI3K/Akt pathways are emerging as candidates for anti-cancer therapy, the mechanism described here might be of clinical relevance. 
MATERIALS AND METHODS
Cell culture and treatments
MDA-MB-
Adhesion force measurements
Single cell force spectroscopy measurement of adhesion forces between tumor cells and endothelial cells using atomic force microscopy (AFM) was performed as previously described in details.
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Static transmigration experiments using time-lapse video imaging
Human cerebral endothelial cells (D3) were cultured until confluence in 12-well plates.
2*10 4 /well tumor cells were plated onto the endothelial monolayer in Leibovitz's L-15 medium (Sigma). Cells were monitored for 6 h using an Andor NEO sCMOS camera connected to a Nikon Eclipse Ti-E inverted microscope, equipped with a home built incubator set to 37°C.
Phase-contrast images were made every 5 min from 5 optical fields/well and time-lapse videos were constructed. The movement of each tumor cell was evaluated and transmigrated cells were counted.
Dynamic transmigration experiments using microfluidics
Design and fabrication of microdevices
To investigate the transmigration of tumor cells under low shear stress conditions we designed and constructed a biocompatible artificial capillary network. The schematic representation of the microfluidic setup is shown in Fig. 1A . The microfluidic capillary device was fabricated from poly-dimethylsiloxane (PDMS, Sylgard 184, Dow Corning Corp.) using standard photolithography and soft lithography techniques. 35 Imprints of the microdevices were built by creating 100 µm high SU8-2050 negative photoresist (MicroChem Corp.) layers on silicon wafers. The photoresist layers were exposed to UV light through a chromium mask (JD PhotoTools Ltd.), using a flood exposure source with mask aligner (500W Hg lamp, i-line, model 97435, Newport Corp. & Digital Exposure Controller model 68945, Newport Corp.). In order to prevent the attachment of PDMS to the SU8 molds, the molds were treated with tridecafluoro-1,1,2,2-tetrahydrooctyl-trichlorosilane (Gelest Inc.) under vacuum overnight. Positive replicas were fabricated by PDMS molding. The PDMS replicas were cured, inlet holes and bubble traps were punched and the devices were bound to PDMS-covered microscope glass slides using oxygen plasma treatment.
Cell seeding and microfluidic cell culture
Prior to seeding of brain endothelial cells, the inner surface of the channels was coated with rat tail collagen. 10 6 D3 cells were collected in 100 μl Leibovitz's L-15 media completed with 2.5% FBS (Sigma), growth factor mix (Lonza), hydrocortisone and gentamicin-amphotericin-B and injected into the microchannels. The microfluidic devices were placed in a home built incubator installed on a microscope stage set to 37°C. Cells were kept in "static conditions" for 24-36 h to reach a confluent layer. During this static state the D3 medium was refreshed every 8 h. When the confluent endothelial layer fully developed, a continuous flow at 300 μl/h rate was started and maintained for 24 h to mimic the blood circulation.
During the transmigration experiments 3*10 5 tumor cells were collected in 100 μl media and injected manually (with syringe). After the injection, a continuous flow with 100 μl/h rate was established and maintained for 6 h. Considering the physical parameters of the device (channel height of ~100 μm, channel width of ~240-480 μm) and the used fluid flow rates (100-300 μl/h), we can estimate the shear stress (based on 36 ) acting on the endothelial cells in the microchannels. The applied fluid flow generated a low stress regime in our device, in which the shear stress was around ~0.3-2 dyn/cm 2 .
Microscopy
Phase contrast microscopy images were taken during the cell culturing and the transmigration experiments, using an Andor NEO sCMOS camera and a Nikon Eclipse Ti-E microscope (Nikon 
Real-time impedance monitoring
To monitor the effects of EHT1864 and LY294002 on D3 cells in real-time, we measured the electrical impedance using the xCELLigence system following the manufacturer's instructions Claudin-5 western-blot was performed from the RIPA-soluble fraction. One representative blot and densitometry based on three independent experiments is shown. * = P<0.05 compared to control, as assessed by ANOVA and Bonferroni's post-hoc test.
